Inoviem is a Biotech and Bioanalytical company, which is supporting Pharma and Biotech companies in achieving their goals in both preclinical and clinical development by optimizing time and resources in the entire drug discovery process. Inoviem reconciles Technology and Physiology with a Patient-Centric approach, enabling drug developers to gain higher precision in the understanding of clinical Mode of Action (MoA), so that a drug candidate can move rapidly to clinical trials. Inoviem is accelerating and securing the entire drug development process, by incorporating clinical reality into early discovery, preclinical, and clinical drug development programs. Inoviem’s expertise in drug-target interaction analysis is based on its label-free platforms PIMS®, NPOT® and LIpS able to decipher the protein network triggered by the drug within a physiological environment, directly on non-modified patients’ tissues. These platforms place Inoviem at the leading position in identification of therapeutic mode of actions of drugs in development. Application of Inoviem’s platforms are: - Understand the mode of action of your compound - Ex-vivo Pharmacology assays - Indication prioritization - Establish Ex-vivo disease models - Validate drug targets in disease models - Choose the compound for development - Identify secondary and OFF targets - Validate target in targeted organism - Patient stratification - Identify biomarkers We believe science is meaningless unless it serves living beings, either directly or indirectly. Therefore, our mission is to improve patient’s life by speeding up the development of new medicines with our science.